Login / Signup

Structure of the dopamine D3 receptor bound to a bitopic agonist reveals a new specificity site in an expanded allosteric pocket.

Sandra Arroyo-UreaAntonina L NazarovaÁngela Carrión-AntolíAlessandro BonifaziFrancisco O BattitiJordy Homing LamAmy Hauck NewmanVsevolod KatritchJavier García-Nafría
Published in: Research square (2023)
Although aminergic GPCRs are the target for ~25% of approved drugs, developing subtype selective drugs is a major challenge due to the high sequence conservation at their orthosteric binding site. Bitopic ligands are covalently joined orthosteric and allosteric pharmacophores with the potential to boost receptor selectivity, driven by the binding of the secondary pharmacophore to non-conserved regions of the receptor. Although bitopic ligands have great potential to improve current medications by reducing off-target side effects, the lack of structural information on their binding mode impedes rational design. Here we determine the cryo-EM structure of the hD 3 R coupled to a G O heterotrimer and bound to the D 3 R selective bitopic agonist FOB02-04A. Structural, functional and computational analyses provide new insights into its binding mode and point to a new TM2-ECL1-TM1 region, which requires the N-terminal ordering of TM1, as a major determinant of subtype selectivity in aminergic GPCRs. This region is underexploited in drug development, expands the established secondary binding pocket in aminergic GPCRs and could potentially be used to design novel and subtype selective drugs.
Keyphrases
  • binding protein
  • small molecule
  • dna binding
  • healthcare
  • molecular dynamics
  • molecular docking
  • risk assessment
  • human health
  • climate change
  • social media
  • drug administration